“纾困”反“被困”，华创证券追讨17.61亿

Group 1 - Huachuang Securities has filed a lawsuit against major shareholders of Guizhou Bailing, involving a total amount exceeding 1.7 billion yuan [2][5] - The dispute originates from a rescue plan initiated in 2019, where Huachuang Securities provided 1.4 billion yuan in funding in exchange for an 11.54% equity stake in Guizhou Bailing [5] - Huachuang Securities has requested the courts to order the repayment of the principal amount of 1.4 billion yuan and 361 million yuan related to stock pledge loans, along with associated fees [5] Group 2 - Guizhou Bailing, established in 1999, is a pharmaceutical company known for its products such as Yindan Xinnaotong soft capsules and Xiaoer Cha Gui Tui Re granules [6] - The company faced a negative internal control audit report in 2023, leading to a temporary suspension of its stock trading, but has since rectified the issues and resumed trading [6] - For the fiscal year 2024, Guizhou Bailing reported revenues of 3.825 billion yuan and a net profit of 33.62 million yuan, although its core business still shows a loss [6][7]